SAREPTA THERAPEUTICS, INC. (SRPT) Operating Margin
- Operating margin · 12 months: Value -10.24%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -10.24% | Operating income / revenue. Period ending 2026-06-30. $-143.25M ÷ $1.40B × 100 ≈ -10.24% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -143.25M USD | Operating Income (Loss) |
| Revenue | 1.40B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | 436.74M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-143.25M | $1.40B | (m) | (m) | $436.74M | -10.24% |
| 2026-03-31 | $-40.96M | $1.58B | (m) | (m) | $467.04M | -2.59% |
| 2025-12-31 | $-699.78M | $1.86B | (m) | (m) | $491.72M | -37.54% |
| 2025-09-30 | $-126.52M | $2.13B | (m) | (m) | $527.29M | -5.93% |
| 2025-06-30 | $-932.00K | $2.19B | (m) | (m) | $563.60M | -0.04% |
| 2025-03-31 | $-117.21M | $2.04B | (m) | (m) | $564.50M | -5.75% |
| 2024-12-31 | $218.08M | $1.79B | (m) | (m) | $557.87M | 12.20% |
| 2024-09-30 | $81.03M | $1.51B | (m) | (m) | $525.70M | 5.35% |
| 2024-06-30 | $37.99M | $1.39B | (m) | (m) | $518.39M | 2.72% |
| 2024-03-31 | $-94.83M | $1.27B | (m) | (m) | $498.16M | -7.45% |
| 2023-12-31 | $-267.82M | $1.14B | (m) | (m) | $481.87M | -23.39% |
| 2023-09-30 | $-399.28M | $1.02B | (m) | (m) | $470.65M | -39.31% |
| 2023-06-30 | $-509.80M | $914.19M | (m) | (m) | $454.54M | -55.76% |
| 2023-03-31 | $-587.41M | $886.44M | (m) | (m) | $490.30M | -66.27% |
| 2022-12-31 | $-536.20M | $843.77M | (m) | (m) | $451.42M | -63.55% |
| 2022-09-30 | $-535.18M | $786.56M | (m) | (m) | $409.00M | -68.04% |
| 2022-06-30 | $-438.28M | $745.70M | (m) | (m) | $365.34M | -58.78% |
| 2022-03-31 | $-394.73M | $676.30M | (m) | (m) | $283.37M | -58.37% |
| 2021-12-31 | $-459.71M | $612.40M | (m) | (m) | $282.66M | -75.07% |
| 2021-09-30 | $-524.61M | $556.32M | (m) | (m) | $290.65M | -94.30% |
| 2021-06-30 | $-627.22M | $510.84M | (m) | (m) | $304.90M | -122.78% |
| 2021-03-31 | $-598.00M | $480.34M | (m) | (m) | $306.24M | -124.49% |
| 2020-12-31 | $-564.16M | $455.87M | (m) | $722.34M | $317.88M | -123.76% |
| 2020-09-30 | $-623.67M | $433.33M | (m) | (m) | $313.25M | -143.92% |
| 2020-06-30 | $-610.19M | $410.95M | (m) | (m) | $313.31M | -148.48% |
| 2020-03-31 | $-747.20M | $394.27M | (m) | (m) | $307.01M | -189.52% |
| 2019-12-31 | $-705.56M | $380.83M | (m) | $560.91M | $284.81M | -185.27% |
| 2019-09-30 | $-614.71M | $365.13M | (m) | (m) | $267.61M | -168.35% |
| 2019-06-30 | $-561.22M | $344.58M | (m) | $436.61M | $245.22M | -162.87% |
| 2019-03-31 | $-389.28M | $323.44M | (m) | $446.19M | $224.99M | -120.35% |
| 2018-12-31 | $-343.63M | $301.03M | (m) | $401.84M | $207.76M | -114.15% |
| 2018-09-30 | $-227.41M | $273.90M | (m) | $300.08M | $175.76M | -83.03% |
| 2018-06-30 | $-203.22M | $241.36M | (m) | $247.73M | $150.89M | -84.20% |
| 2018-03-31 | $-163.13M | $202.85M | (m) | $183.79M | $139.81M | -80.42% |
| 2017-12-31 | $-171.64M | $154.58M | (m) | $166.71M | $122.68M | -111.03% |
| 2017-09-30 | $-236.89M | $102.73M | (m) | $193.01M | $113.40M | -230.60% |
| 2017-06-30 | $-247.51M | (m) | (m) | $193.13M | $107.41M | (m) |
| 2017-03-31 | $-246.27M | (m) | (m) | $178.56M | $89.09M | (m) |
| 2016-12-31 | $-266.73M | $5.42M | (m) | $188.27M | $83.75M | -4920.31% |
| 2016-09-30 | $-242.79M | (m) | (m) | $158.90M | (m) | (m) |
| 2016-06-30 | $-238.02M | (m) | (m) | $161.22M | (m) | (m) |
| 2016-03-31 | $-218.02M | (m) | (m) | $146.06M | (m) | (m) |
| 2015-12-31 | $-220.18M | (m) | (m) | $146.39M | (m) | (m) |
| 2015-09-30 | $-200.45M | (m) | (m) | $135.85M | (m) | (m) |
| 2015-06-30 | $-182.37M | (m) | (m) | $121.03M | (m) | (m) |
| 2015-03-31 | $-170.53M | (m) | (m) | $112.49M | (m) | (m) |
| 2014-12-31 | $-133.79M | (m) | (m) | $94.23M | (m) | (m) |
| 2014-09-30 | $-121.92M | (m) | (m) | $88.47M | (m) | (m) |
| 2014-06-30 | $-113.17M | (m) | (m) | $87.71M | (m) | (m) |
| 2014-03-31 | $-99.99M | (m) | (m) | $80.05M | (m) | (m) |
| 2013-12-31 | $-90.28M | (m) | (m) | $72.91M | (m) | (m) |
| 2013-09-30 | $-67.80M | (m) | (m) | $60.67M | (m) | (m) |
| 2013-06-30 | $-49.77M | (m) | (m) | $50.49M | (m) | (m) |
| 2013-03-31 | $-38.24M | (m) | (m) | $51.36M | (m) | (m) |
| 2012-12-31 | $-29.70M | (m) | (m) | $52.40M | (m) | (m) |
| 2012-09-30 | $-28.34M | (m) | (m) | $58.27M | (m) | (m) |
| 2012-06-30 | $-32.70M | (m) | (m) | $62.97M | (m) | (m) |
| 2012-03-31 | $-37.27M | (m) | (m) | $66.87M | (m) | (m) |
| 2011-12-31 | $-35.93M | (m) | (m) | $66.86M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-20.93M | (m) | (m) | $35.97M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-15.51M | (m) | (m) | $24.40M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |